James Eubanks, PhD, received a doctorate in neurobiology and behavior from the University of Washington in 2000. After conducting postdoctoral studies at the University of Chicago and the University of Washington, Dr. Eubanks accepted a position at Boehringer Ingelheim as a medical science liaison specializing in Parkinson’s disease (PD). This role allowed him to engage with key opinion leaders in the PD field. At Teva Pharmaceuticals, he was involved in trials of rasagiline, a drug that showed a modest but significant ability to slow PD progression. Dr. Eubanks is currently the director of medical affairs for Octave, where he is overseeing the translation of a precision medicine platform for Multiple Sclerosis (MS) into routine clinical use among neurologists. He hopes to employ a similar, biomarker-based approach to develop effective disease-modifying therapies that will improve the lives of people with PD.